 AUSTIN, Texas, Aug. 13, 2021 GLOBE NEWSWIRE -- Plus Therapeutics, Inc. Nasdaq: PSTV the Company, a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare and difficult-to-treat cancers, today announced it will present data on Rhenium-186 NanoLiposome 186RNL from its Phase 1 ReSPECTTM clinical trial in recurrent glioblastoma GBM at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting AANS being held virtually August 21-25, 2021. 